Martin & Harris Unlisted Share Price

Martin and Harris Laboratories Limited Unlisted Share – Company Overview

MARTIN AND HARRIS LABORATORIES LIMITED was first established in 1996 and is based in Gurgaon, Haryana. The company is a part of Apeejay Group, which is India’s oldest and largest Conglomerates. Apeejay Group is a leading Industrial & Investment house with businesses in Automotive, Chemicals & Plastics, Distribution, Logistics & Retail, Pharmaceuticals & life sciences, real estate, and international trading and a nascent presence in IT, merchant banking & financial services and publishing.

Martin and Harris Laboratories Limited is primarily engaged in the business of manufacturing pharmaceuticals, medicinal chemicals & botanical products. The company intensively focuses on drugs used for Hyper Tension, High blood pressure, and heart attack. Apart from its primary business, the company also undertakes fund management through investment in different avenues like mutual funds, equity, etc.

Martin and Harris Laboratories Limited has two units located at Roorkee, Uttarakhand, and Una in Himachal Pradesh. The company is continuously striving to expand its manufacturing facilities and meet global standards.

The company was awarded ‘Best Pharma Excellence awards’ in 2018 by ASSOCHAM India.

MARTIN & HARRIS Share Price, Share Details as of March 31, 2025

Martin And Harris Laboratories Limited Incorporation Details

Martin And Harris Laboratories Limited Principal Business Activities

Martin And Harris Laboratories Limited Board of Directors

MR. S. L. LAAD

MR. Nasim Uddin

MR. Vivek Manohar Padgaonkar

MR. H. S. THAKUR

MR. Ashok Chandra Sen

Martin And Harris Laboratories Particular of Subsidiary Companies

Industry Outlook

 Indian Pharmaceutical market ranks as 3rd largest in the world in terms of volume and 14th largest in terms of value. Healthcare has become one of the largest sectors of the Indian economy, in terms of both employment and revenue. India is known as the Pharmacy of the world and is the largest provider of generic drugs at a global level. The pharmaceutical industry of India supplies over 50% of the global demand for various vaccines, 40% of generic demands in the USA, and 25% of all the medicines in the United Kingdom. Excellent Research & Development, low cost of labor, availability of management and technical personnel, and local equipment’s availability has helped India to manufacture pharma products at a very low cost.

The Indian healthcare market may see a 3 fold jump in terms of value to reach US$ 372 billion by FY 2022. The growth can be attributed to rising income, greater health awareness, increased precedence of lifestyle disease, and Indian prominence in making medicinal products for the treatment of COVID 19. India aims to achieve vaccination for COVID-19 of 30 Crore people in the next few months.

Export of Pharmaceuticals products from India stood at US$ 16.8 billion in FY 2020 and US$ 2.07 billion in the month of October 2020. In the first 3 quarters of FY 2021, India exported pharmaceuticals worth US$ 15.86 billion. India supplied around 45 tons and 400 million tablets of hydroxychloroquine to around 114 countries globally to treat the covid patients in the initial stage of the covid-19 pandemic. Exports in FY 2021 of Indian pharma products are expected to cross US$ 24 billion, increasing by over 16% when compared to FY 2020.

After the onset of COVID 19, the Indian pharmaceutical sector became the busiest sector in the Indian economy. The pandemic proved to be a boon in disguise for the Indian pharmaceutical sector.

FAQ's on Martin and Harris

Q: What is the face value of Martin & Harris Laboratories Ltd shares?
Answer: The face value of Martin & Harris Laboratories Ltd is ₹10 per equity share.

Q: What is the minimum lot size for buying Martin & Harris Laboratories shares through WWIPL?
Answer: The minimum lot size for Martin & Harris Laboratories shares is 100 equity shares.

Q: How can I buy Martin & Harris Laboratories unlisted shares through WWIPL?
Answer: Investors can complete KYC, confirm the transaction details through WWIPL, transfer funds, and receive shares directly in their Demat account.

Q: Why should I buy Martin & Harris Laboratories shares through WWIPL?
Answer: WWIPL offers transparent pricing, secure transactions, seamless Demat transfers, and dedicated support throughout the investment process.

Q: Is investing in Martin & Harris Laboratories Ltd a good idea?
Answer: Investors often evaluate Martin & Harris Laboratories based on its pharmaceutical manufacturing capabilities, product portfolio, financial performance, and long-term demand in the healthcare sector.

Q: Why do investors buy Martin & Harris Laboratories shares before a potential IPO?
Answer: Investors seek early exposure to a pharma company before a potential listing, aiming to participate in future value creation and liquidity opportunities.

Q: What business does Martin & Harris Laboratories Ltd operate in?
Answer: Martin & Harris Laboratories Ltd is engaged in the manufacturing and distribution of pharmaceutical products, including formulations and healthcare-related products.

Q: What makes Martin & Harris Laboratories different from other unlisted pharma companies?
Answer: The company focuses on pharmaceutical formulations with an emphasis on quality manufacturing and distribution across healthcare markets.

Q: What are the key growth drivers for Martin & Harris Laboratories Ltd?
Answer: Rising healthcare demand, expansion of pharmaceutical distribution, product diversification, regulatory approvals, and growth in domestic healthcare spending are key growth drivers.

Q: What factors affect the valuation of Martin & Harris Laboratories shares?
Answer: Revenue growth, product pipeline, margins, regulatory compliance, manufacturing capacity, profitability, and demand for pharmaceutical products influence valuation.

Q: Are Martin & Harris Laboratories shares available in Demat form?
Answer: Yes. Shares purchased through WWIPL are transferred directly to the investor's Demat account.

Q: Can I sell my Martin & Harris Laboratories shares through WWIPL?
Answer: Yes. WWIPL facilitates both buying and selling of unlisted shares, subject to market demand and availability.

Q: What documents are required to buy Martin & Harris Laboratories shares through WWIPL?
Answer: Investors generally need PAN, Aadhaar, Client Master Report (CMR), and bank account details to complete the transaction.

Q: What are the risks of investing in Martin & Harris Laboratories shares?
Answer: Investors should consider regulatory risks, product approvals, competition in pharma, pricing pressure, and liquidity constraints associated with unlisted shares.

Q: How does WWIPL help investors track Martin & Harris Laboratories investments?
Answer: WWIPL provides company updates, transaction assistance, market insights, and investment support to help investors stay informed.

Q: How long does it take for Martin & Harris Laboratories shares purchased through WWIPL to be credited to a Demat account?
Answer: Shares are generally transferred to the investor's Demat account after successful completion and verification of the transaction.

Q: What should investors evaluate before investing in Martin & Harris Laboratories Ltd?
Answer: Investors should assess the company's product pipeline, regulatory approvals, manufacturing strength, financial performance, profitability, valuation, and long-term pharmaceutical market demand.

Q: Can Martin & Harris Laboratories benefit from India's growing pharmaceutical industry?
Answer: Yes. Rising healthcare demand, increasing domestic pharma consumption, and export opportunities may create long-term growth potential for the company.